An Open Label Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2516 After Oral Administration to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 2516 (Primary)
- Indications Neuropathic pain
- Focus Pharmacokinetics
- 29 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 29 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2009 New trial record